Vyxeos liposomal (previously Vyxeos)
What Vyxeos liposomal (previously Vyxeos) is used for
Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Vyxeos liposomal (previously Vyxeos)
- Active substance
- daunorubicin;cytarabine
- Disease area
- Leukemia, Myeloid, Acute
- Medicine group
- Antineoplastic agents
- ATC code
- L01XY01
- Marketing authorisation holder
- Jazz Pharmaceuticals Ireland Limited
- Authorised in the EU since
- 2018
Official information
In the USA
Same active substance: Vyxeos
In India
- Daunorubicin hydrochloride: 5 brands in India
- Cytarabine: 36 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Vyxeos liposomal (previously Vyxeos) used for?
Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
What is the active substance in Vyxeos liposomal (previously Vyxeos)?
Vyxeos liposomal (previously Vyxeos) contains daunorubicin;cytarabine.
Who makes Vyxeos liposomal (previously Vyxeos)?
The EU marketing authorisation holder is Jazz Pharmaceuticals Ireland Limited.
Is Vyxeos liposomal (previously Vyxeos) an orphan medicine?
Yes. Vyxeos liposomal (previously Vyxeos) is designated an orphan medicine in the EU, for a rare disease (Leukemia, Myeloid, Acute).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU